David Ross Smith Charles River Laboratories International, Inc. (CRL) insider trading activity

David Ross Smith is Corporate Executive VP & CFO of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Currently has a direct ownership of 25,819 shares of CRL, which is worth approximately $4.81 Million. The most recent transaction as insider was on Mar 03, 2022, when has been sold 8,965 shares (Common Stock) at a price of $283.44 per share, resulting in proceeds of $2,541,040. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 25.8K

0% 3M change

0% 12M change

Total Value Held $4.81 Million

David Ross Smith Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2022	SELL Open market or private sale	$2,541,040 $283.44 p/Share	8,965 Reduced 25.77%	25,819 Common Stock
Mar 03 2022	BUY Exercise of conversion of derivative security	$1,295,980 $144.56 p/Share	8,965 Added 20.49%	34,784 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	5,152 Added 16.63%	25,819 Common Stock
Feb 23 2022	SELL Payment of exercise price or tax liability	$108,303 $289.58 p/Share	374 Reduced 1.78%	20,667 Common Stock
Feb 22 2022	SELL Payment of exercise price or tax liability	$100,121 $293.61 p/Share	341 Reduced 1.59%	21,041 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$1,674,855 $312.24 p/Share	5,364 Reduced 20.06%	21,382 Common Stock
Jan 28 2022	BUY Grant, award, or other acquisition	-	12,321 Added 31.54%	26,746 Common Stock
Aug 09 2021	SELL Open market or private sale	$712,512 $407.15 p/Share	1,750 Reduced 10.82%	14,425 Common Stock
May 28 2021	BUY Grant, award, or other acquisition	-	1,313 Added 7.51%	16,175 Common Stock
May 04 2021	SELL Open market or private sale	$1,123,733 $340.01 p/Share	3,305 Reduced 18.19%	14,862 Common Stock
May 04 2021	BUY Exercise of conversion of derivative security	$478,134 $144.67 p/Share	3,305 Added 15.39%	18,167 Common Stock
Apr 22 2021	SELL Open market or private sale	$1,268,850 $330.0 p/Share	3,845 Reduced 20.55%	14,862 Common Stock
Apr 22 2021	BUY Exercise of conversion of derivative security	$420,412 $109.34 p/Share	3,845 Added 17.05%	18,707 Common Stock
Apr 15 2021	SELL Open market or private sale	$640,000 $320.0 p/Share	2,000 Reduced 11.86%	14,862 Common Stock
Mar 01 2021	SELL Open market or private sale	$1,266,664 $290.12 p/Share	4,366 Reduced 20.57%	16,862 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	$384,426 $88.05 p/Share	4,366 Added 17.06%	21,228 Common Stock
Feb 24 2021	SELL Payment of exercise price or tax liability	$81,781 $282.98 p/Share	289 Reduced 1.69%	16,862 Common Stock
Feb 23 2021	SELL Payment of exercise price or tax liability	$77,136 $283.59 p/Share	272 Reduced 1.57%	17,031 Common Stock
Feb 22 2021	SELL Payment of exercise price or tax liability	$71,519 $289.55 p/Share	247 Reduced 1.41%	17,303 Common Stock
Jan 29 2021	SELL Payment of exercise price or tax liability	$990,040 $260.88 p/Share	3,795 Reduced 17.78%	17,550 Common Stock
Jan 29 2021	BUY Grant, award, or other acquisition	-	14,234 Added 40.01%	21,345 Common Stock
Jan 25 2021	SELL Bona fide gift	-	8,656 Reduced 54.9%	7,111 Common Stock
Jan 04 2021	SELL Open market or private sale	$1,246,700 $249.34 p/Share	5,000 Reduced 24.08%	15,767 Common Stock

Also insider at

FTRE

Fortrea Holdings Inc.

Director

DRS

David Ross Smith

Corporate Executive VP & CFO

Wilmington, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRL shares.

Notify only if

Value

Insider Trading

Get notified when an Charles River Laboratories International, Inc. insider buys or sells CRL shares.

Notify only if

Operation

Value

Type

News

Receive news related to CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Track Activities on CRL

Account